Screener
CorMedix CRMD Operating Income
Discontinued — last reported Q1 '26
Operating Income at other companies
Other financials
Where this comes from
Reported directly by CorMedix in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: CorMedix’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001410098-26-000021
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Selling and marketing | 12,532 | 4,474 |
| General and administrative | 21,720 | 9,693 |
| Total Operating Expenses | 41,464 | 17,360 |
| Income From Operations | 63,658 | 20,125 |
| Other (Expense) Income: | ||
| Unrealized loss on marketable security | (3,546) | - |
| Change in contingent consideration | (4,199) | - |
| Other non-operating (expense) income, net | (268) | 519 |
Item 1. Unaudited Condensed Consolidated Financial Statements.
FAQ
- What is CorMedix's operating income?
- CorMedix (CRMD) reported operating income of $63.66M in Q1 2026.
- How has CorMedix's operating income changed year-over-year?
- CorMedix's operating income increased by 216.3% year-over-year, from $20.13M to $63.66M.
- What is the long-term trend for CorMedix's operating income?
- Over 3 years (2021 to 2025), CorMedix's operating income has grown at a 72.1% compound annual growth rate (CAGR), from -$29.44M to $150.14M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about CorMedix's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude